newsfilter
← Earnings
Earnings Releases·

AchieveRx — Third Quarter 2026 Earnings Summary

AchieveRx, formerly Achieve Life Sciences, reported third-quarter 2026 financial results with cash, cash equivalents, and marketable securities totaling $201.5 million as of September 30, 2026. The company presented 52-week ORCA-OL trial data showing that 39.4% of participants new to cytisinicline achieved four-week continuous abstinence by the end of treatment. AchieveRx completed three commercial-scale stability batches for U.S. manufacturing and remains on track to resubmit its New Drug Application in the fourth quarter of 2026. The organization also rebranded as AchieveRx, The Quit Company, and expanded its leadership team with new appointments for Chief Financial Officer and Senior Vice President of Marketing and Communications.

Company
ACHIEVE LIFE SCIENCES INC
Sector
Healthcare
Industry
Biotechnology